EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2493
https://www.valueinhealthjournal.com/article/S1098-3015(23)02683-9/fulltext
Title :
EE514 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02683-9&doi=10.1016/j.jval.2023.03.2493
First page :
Section Title :
Open access? :
No
Section Order :
10287